Spectrum Announces Poziotinib Data Being Presented at the IASLC 2019 World Conference on Lung Cancer
September 06 2019 - 4:30PM
Business Wire
Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a
biopharmaceutical company focused on novel and targeted oncology
therapies, is developing poziotinib in non-small cell lung cancer
(NSCLC) EGFR exon 20 mutations and beyond. New clinical data from
the poziotinib Phase 2 investigator-initiated trial in NSCLC EGFR
exon 20 mutations, conducted by the University of Texas MD Anderson
Cancer Center will be presented during the IASLC 2019 World
Conference on Lung Cancer hosted by the International Association
for the Study of Lung Cancer taking place in Barcelona, Spain from
September 7-10, 2019.
“There continues to be investigator interest in poziotinib’s
unique characteristics to address NSCLC mutations, including exon
20 and other mutations, which have limited or no treatment
options,” said Francois Lebel, M.D., F.R.C.P.C., Chief Medical
Officer of Spectrum Pharmaceuticals. “The data presented at this
conference by our scientific collaborators at MD Anderson further
expands the body of evidence supporting poziotinib’s role in lung
cancer and helps us gain new insights into its full potential.”
Abstracts of interest include:
- Activity of Poziotinib and Other 2nd-Gen Quinazoline EGFR
TKIs in Atypical Exon18 and Acquired Osimertinib Resistance
Mutants Abstract P1.14-08, Targeted Therapy Track, poster
presentation, Sunday, September 8, 9:45 am – 6:00 pm CET in Fira De
Barcelona, Gran Via, Exhibit Hall
- Identification of Mechanisms of Acquired Resistance to
Poziotinib in EGFR Exon 20 Mutant Non-Small Cell Lung Cancer
(NSCLC) Abstract MA09.03, Targeted Therapy Track, mini oral
session, Sunday, September 8, 3:25-3:30 pm CET at Fira De
Barcelona, Gran Via, Room Melbourne (1991)
Full abstracts can be found by visiting
https://library.iaslc.org/conference-program?product_id=15.
“NSCLC patients with exon 20 insertion mutations have a poor
prognosis and very limited treatment options. We are diligently
developing poziotinib and look forward to topline results from
cohort 1 of our Spectrum-sponsored Phase 2 study in the fourth
quarter,” said Joe Turgeon, President and CEO of Spectrum
Pharmaceutical.
About Poziotinib
Poziotinib is a novel, oral epidermal growth factor receptor
tyrosine kinase inhibitor (EGFR TKI) that inhibits the tyrosine
kinase activity of EGFR (HER1) as well as HER2 and HER4.
Importantly this leads to the inhibition of the proliferation of
tumor cells that overexpress these receptors. Mutations or
overexpression/amplification of EGFR family receptors have been
associated with a number of different cancers, including non-small
cell lung cancer (NSCLC), breast cancer, and gastric cancer. The
full poziotinib targeted therapy clinical program is focused on
four development areas for EGFR and HER2 mutations, including
previously treated NSCLC, first-line NSCLC, treatment of other
solid tumors and combination therapy.
Spectrum received exclusive license from Hanmi Pharmaceuticals
to develop, manufacture, and commercialize poziotinib worldwide,
excluding Korea and China. Poziotinib is currently being
investigated by Spectrum and Hanmi in several trials in multiple
solid tumors.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a biopharmaceutical company focused
on acquiring, developing, and commercializing novel and targeted
drug products, with a primary focus in hematology and oncology.
Spectrum has a strong track record of successfully executing across
the biopharmaceutical business model, from in-licensing and
acquiring differentiated drugs, clinically developing novel assets,
successfully gaining regulatory approvals and commercializing in a
competitive healthcare marketplace. Spectrum has a late-stage
pipeline with novel assets that serve areas of unmet need. This
pipeline has the potential to transform the company in the near
future.
Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute
“forward-looking statements” within the meaning of the United
States Private Securities Litigation Reform Act of 1995, as amended
to date. These forward-looking statements relate to a variety of
matters, including, without limitation, statements that relate to
Spectrum’s business and its future, including the Company’s ability
to advance development of its late-stage pipeline assets, the
ability of poziotinib to meet currently unaddressed medical needs
and the size of the potential markets, the timing of the results of
cohort 1 and cohort 2 in Spectrum’s ZENEITH20 clinical trial, the
future potential of Spectrum’s existing drug pipeline, the
progression of the poziotinib development program and other
statements that are not purely statements of historical fact. These
forward-looking statements are made on the basis of the current
beliefs, expectations, and assumptions of the management of
Spectrum and are subject to significant risks and uncertainties
that could cause actual results to differ materially from what may
be expressed or implied in these forward-looking statements. Risks
that could cause actual results to differ include, but are not
limited to, the uncertainties inherent in new product development,
including clinical trial results and additional analysis of
existing pre-clinical and clinical data, the possibility that
Spectrum's new and existing drug candidates, including poziotinib,
may not ultimately prove to be safe or effective, the possibility
that Spectrum's new and existing drug candidates, if approved, may
not be more effective, safer, or more cost efficient than competing
drugs, and other risks that are described in further detail in the
Company's reports filed with the Securities and Exchange
Commission. The Company does not plan to update any such
forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law. For a further discussion of risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of Spectrum in general, see the risk
disclosures in the Annual Report on Form 10-K of Spectrum for the
year ended December 31, 2018, and in subsequent reports on Forms
10-Q and 8-K and other filings made with the SEC by Spectrum.
SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of
Spectrum Pharmaceuticals, Inc and its affiliate. REDEFINING CANCER
CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned
by Spectrum Pharmaceuticals, Inc. Any other trademarks are the
property of their respective owners.
© 2019 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190906005478/en/
Shiv Kapoor Vice President, Strategic Planning & Investor
Relations 702-835-6300 InvestorRelations@sppirx.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2023 to Apr 2024